Cargando…

Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor

Detalles Bibliográficos
Autores principales:	Chen, Shumin, Li, Ye, Wang, Zheng, Feng, Lin, Jia, Yueping, Mo, Xiaodong, Wang, Yu, Jiang, Qian, Huang, Xiaojun, Lai, Yueyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309510/ https://www.ncbi.nlm.nih.gov/pubmed/36806200 http://dx.doi.org/10.1097/CM9.0000000000002481

Ejemplares similares

The advantage of chimeric antigen receptor T cell therapy in pediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series
por: Wu, Shuiyan, et al.
Publicado: (2021)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

TCF3-HLF-Positive Acute Lymphoblastic Leukemia Resembling Burkitt Leukemia: Cell Morphologic and Immunophenotypic Findings
por: Li, Meng-Ju, et al.
Publicado: (2022)

TCF3::HLF acute lymphoblastic leukemia: still challenging to cure thirty years later
por: Tasian, Sarah K.
Publicado: (2023)

CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation
por: Xu, Qianwen, et al.
Publicado: (2022)

CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
por: Yao, Zhenzhen, et al.
Publicado: (2023)

Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia
por: Leonard, Jessica, et al.
Publicado: (2021)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
por: Summers, Ryan J., et al.
Publicado: (2022)

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia
por: An, Furun, et al.
Publicado: (2020)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia
por: Zhang, Xian, et al.
Publicado: (2020)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

The hirudin-like factors HLF3 and HLF4—hidden hirudins of European medicinal leeches
por: Müller, Christian, et al.
Publicado: (2020)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia
por: Fu, Zexin, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: history, current situation, and future
por: Muller, Bradley J., et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
por: Ding, Jing, et al.
Publicado: (2022)

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
por: Fischer, Ute, et al.
Publicado: (2015)

Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
por: Wang, Haiyong, et al.
Publicado: (2021)

The goat β-casein/CMV chimeric promoter drives the expression of hLF in transgenic goats produced by cell transgene microinjection
por: Zhang, Ting, et al.
Publicado: (2019)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

The prospects and challenges of chimeric antigen receptor T cell therapy for head and neck squamous cell carcinoma
por: Liu, Wei, et al.
Publicado: (2023)

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2
por: Wang, Xiaoming, et al.
Publicado: (2016)

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
por: Driouk, Lina, et al.
Publicado: (2020)

Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
por: Feng, Jingjing, et al.
Publicado: (2022)

Short tail stories: the hirudin-like factors HLF6 and HLF7 of the Asian medicinal leech, Hirudinaria manillensis
por: Müller, Christian, et al.
Publicado: (2021)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
por: Liu, Shuangyou, et al.
Publicado: (2020)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia
por: Emole, Josephine, et al.
Publicado: (2023)

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy
por: Wang, Chengji, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma
por: Wang, Zaiyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_on2g72kuec948b3gfoaa2lhlq8